Oncolytics Biotech is trading 10.22% down at $0.50, with the cause of the October 12, 2026 decline unconfirmed. - The company reported accelerating enrollment in its REO 033 study on October 11, but available reporting does not link the update to the selloff. - Major U.S. indexes were mixed and showed only modest moves, which does not establish a broad-market explanation.